Alloy Women's Health: Clinical Gaps and Limitations You Should Know

What Alloy Actually Offers

Alloy provides online access to FDA-approved menopausal hormone therapy without requiring in-person visits. The intake process is questionnaire-driven. A clinician reviews the answers and, if appropriate, issues a prescription that ships directly to the patient.

The core formulary centers on transdermal estradiol (the 0.05 mg/day and 0.1 mg/day patch strengths) and oral micronized progesterone (Prometrium, 100 mg or 200 mg). This aligns with the first-line choices recommended by the North American Menopause Society (NAMS) 2022 Position Statement, which states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy women within 10 years of menopause or under age 60." [1]

What the Questionnaire Does and Does Not Capture

The intake questionnaire covers symptom severity, last menstrual period, and contraindications such as personal breast cancer history. What it does not systematically capture is cardiovascular risk stratification using validated tools, a detailed family history of venous thromboembolism (VTE), or a structured review of medications that interact with estrogen metabolism, including rifampin and certain anticonvulsants. [2]

A questionnaire-only intake can miss a patient whose 10-year atherosclerotic cardiovascular disease (ASCVD) risk score, calculated via the Pooled Cohort Equations, would place her in a category where the benefit-risk ratio of oral estrogen shifts meaningfully. That calculation requires a lipid panel and blood pressure, neither of which Alloy mandates. [3]

Formulary Scope

Alloy's formulary, while clinically appropriate for uncomplicated cases, is narrow. It does not publicly list:

• Low-dose vaginal estradiol (0.01% cream or the 10 mcg vaginal tablet/ring) for isolated GSM
• Testosterone, which NAMS acknowledges as having evidence for hypoactive sexual desire disorder (HSDD) in postmenopausal women [4]
• Progesterone alternatives such as norethindrone acetate or levonorgestrel-IUD for women who do not tolerate oral micronized progesterone
• Non-hormonal pharmacological options such as fezolinetant (Veozah), the FDA-approved neurokinin 3 receptor antagonist approved in May 2023 [5]

Patients who fail first-line therapy or who have specific contraindications to oral progesterone have limited recourse within the Alloy platform.

The Lab Monitoring Gap: A Concrete Clinical Risk

Alloy does not require baseline or follow-up laboratory testing. This is the single most clinically significant limitation of the platform.

Why Baseline Labs Matter

Before initiating systemic estrogen therapy, NAMS and the Endocrine Society recommend, at minimum, a clinical breast exam or recent mammogram and, where indicated, a pelvic exam and endometrial assessment. [1] [6] Alloy's asynchronous model cannot verify whether a patient's mammography is current, nor can it perform a physical exam.

A 2023 JAMA Internal Medicine study examining direct-to-consumer hormone prescribing found that only 38% of DTC platforms documented confirmation of cancer screening before initiating systemic HRT. [7] Alloy does not publish its own internal compliance rate for this benchmark.

Lipid panels matter because oral estrogen raises triglycerides. In women with baseline triglycerides above 400 mg/dL, oral estrogen is relatively contraindicated; the transdermal route bypasses hepatic first-pass metabolism and carries a lower VTE risk, but this distinction can only be made if lipid data exist. [2]

Follow-Up Monitoring

Once therapy is initiated, dose adjustments at Alloy are handled by messaging. There is no scheduled follow-up lab draw for estradiol levels, which can vary substantially between patients on identical patch doses due to differences in skin absorption. The coefficient of variation for transdermal estradiol serum levels across patients using the same 0.05 mg/day patch has been reported at approximately 30 to 40% in pharmacokinetic studies. [8]

Without serum estradiol levels, a prescriber cannot distinguish between a patient who is under-absorbed and symptomatic versus one who is over-absorbed and at elevated VTE risk, particularly if she carries factor V Leiden or prothrombin gene mutations that were never screened for during intake.

Prescribing Scope: What Alloy Does Not Treat

Complex Cardiovascular and Thrombotic Risk

The Women's Health Initiative (WHI) remains the most cited trial in HRT safety discussions. The conjugated equine estrogen plus medroxyprogesterone acetate arm (N=16,608) showed a hazard ratio of 1.26 (95% CI: 1.00 to 1.59) for breast cancer and a HR of 1.41 (95% CI: 1.07 to 1.85) for stroke after 5.6 years. [9] These findings do not directly apply to bioidentical transdermal estradiol plus micronized progesterone, but they illustrate why individual risk stratification before prescribing matters.

The E3N cohort study (N=80,377 French women) found that transdermal estradiol combined with micronized progesterone did not significantly increase breast cancer risk (RR: 1.00, 95% CI: 0.83 to 1.22) over a mean follow-up of 8.1 years, compared to never-users. [10] This is a key distinction that supports the safety of the Alloy formulary's transdermal approach, but it still requires the provider to confirm the patient is not in a high-risk category at baseline.

Alloy's intake form does not include questions about prior VTE, known thrombophilia, or migraine with aura, all of which are standard contraindication screens in the NAMS and ACOG guidance. [1] [11]

Testosterone and HSDD

Roughly 12 to 19% of postmenopausal women meet criteria for HSDD. [4] Testosterone therapy, prescribed off-label in the United States (there is no FDA-approved female testosterone product as of 2025), has demonstrated efficacy in multiple randomized controlled trials. A 2019 meta-analysis in The Lancet Diabetes and Endocrinology (N=8 trials, 3,176 participants) found that testosterone significantly improved satisfying sexual events, sexual desire, and arousal compared to placebo. [4]

Alloy does not prescribe testosterone. Women seeking this therapy must go elsewhere, which represents a gap for the roughly one in six postmenopausal women who may benefit.

Genitourinary Syndrome of Menopause

GSM affects approximately 50 to 60% of postmenopausal women. [6] Low-dose vaginal estrogen delivers local benefit with negligible systemic absorption (serum estradiol levels remain below 10 pg/mL with the 10 mcg vaginal tablet). [12] Alloy's public formulary does not include vaginal estrogen as an advertised offering, meaning women with isolated GSM who do not have hot flashes may not be served by the platform at all.

Is Alloy Legit? Regulatory and Prescribing Legitimacy

Alloy uses licensed physicians and nurse practitioners. Prescriptions are issued through licensed pharmacies. The medications themselves are FDA-approved. On those measures, Alloy is a legitimate medical service.

The question is not whether Alloy is fraudulent. The question is whether its clinical process meets the standard of care for hormone therapy initiation and management. The answer is: partially.

Where It Meets the Standard

The NAMS 2022 Position Statement supports prescribing transdermal estradiol plus oral micronized progesterone as a first-line regimen for healthy, symptomatic menopausal women under 60 or within 10 years of menopause onset. [1] Alloy prescribes exactly this combination. For the right patient, the platform delivers guideline-concordant therapy conveniently and affordably.

Where It Falls Short

The Endocrine Society's 2015 Menopause Clinical Practice Guideline states: "We recommend that clinicians individualize the choice of HRT preparation based on patient risk factors, preferences, and comorbidities, with appropriate baseline assessment." [6] An asynchronous questionnaire without physical examination or laboratory data does not constitute an appropriate baseline assessment for a non-trivial fraction of users.

A useful clinical framework for evaluating whether a DTC menopause platform meets standard-of-care requirements involves four checkpoints:

1. Contraindication screening completeness. Does intake capture all NAMS and ACOG absolute contraindications, including undiagnosed vaginal bleeding, active liver disease, prior VTE, estrogen-sensitive malignancy, and migraine with aura?
2. Baseline assessment documentation. Is there verification of recent mammography, pelvic exam or Pap (if indicated), and cardiovascular risk markers including blood pressure and lipids?
3. Formulary breadth for treatment failure. Can the platform handle patients who do not respond to or tolerate first-line therapy?
4. Monitoring protocol. Are there scheduled follow-up touchpoints with the option for laboratory review and dose titration based on serum levels?

Alloy scores well on checkpoint 3 only for the narrow subset of patients whose first-line therapy succeeds. On checkpoints 1, 2, and 4, the platform has documented or probable gaps.

Alloy vs. Alternatives: A Direct Comparison

Several other telehealth platforms operate in the menopause and HRT space, including Midi Health, Winona, Gennev, and Evernow. Each has different clinical depth.

Formulary Breadth

Midi Health and Winona publicly list testosterone, vaginal estrogen, and non-hormonal options in addition to systemic HRT. Alloy's public formulary is narrower. For patients who need combination therapy or who have failed a patch-and-progesterone regimen, a broader-formulary platform reduces the need for a secondary provider.

Lab Integration

Some competitors, including certain Midi Health pathways, integrate LabCorp or Quest orders as part of the intake or follow-up process. Alloy does not advertise this capability. Given that the coefficient of variation for transdermal estradiol absorption reaches 30 to 40% between individuals, [8] a platform that never orders labs is managing dose titration without a direct measurement of what the patient is actually absorbing.

Provider Access Mode

Alloy's model is primarily asynchronous. Synchronous video visits allow providers to observe a patient's affect, ask follow-up questions based on responses in real time, and perform a limited visual assessment. The clinical information captured in a synchronous visit exceeds that of a questionnaire, particularly for mental health comorbidities such as depression and anxiety, which overlap substantially with menopause symptom profiles and which affect treatment selection. [13]

Cost

Alloy charges approximately $49, $99/month, covering medication and provider fees. This is competitive. Midi Health charges a membership fee in addition to medication costs. The cost comparison favors Alloy for uncomplicated cases, but cost efficiency must be weighed against the clinical completeness of the service.

Who Should and Should Not Use Alloy

Patients Likely to Benefit

A woman who is 48 to 60 years old, within 10 years of her last period, has confirmed recent mammography, carries no personal history of VTE or estrogen-sensitive malignancy, does not use interacting medications, and has uncomplicated vasomotor symptoms is a reasonable candidate for Alloy's platform. She is precisely the patient for whom transdermal estradiol plus oral micronized progesterone is both guideline-concordant and low-risk.

Patients Who Need More

The following clinical profiles require a higher level of evaluation than Alloy's asynchronous model provides:

• Women with BMI above 35 kg/m2, hypertension, or dyslipidemia, where cardiovascular risk stratification changes the benefit-risk calculus
• Women with prior breast cancer, BRCA1/2 status unknown or positive, or strong first-degree family history of breast cancer
• Women with undiagnosed or irregular uterine bleeding, where endometrial sampling must precede hormone initiation
• Women with a prior VTE event or known thrombophilia
• Women whose primary complaint is HSDD or isolated GSM
• Women more than 10 years post-menopause or older than 60, where the timing hypothesis suggests a different risk profile [1]
• Women on medications with significant estrogen interactions, including rifampin, phenytoin, carbamazepine, and St. John's Wort [2]

Alloy Reviews: What Patient Feedback Reveals Clinically

Patient reviews of Alloy on third-party sites consistently cite ease of access and affordability as strengths. The clinical gaps described above do not typically appear in lay reviews because most patients lack the clinical vocabulary to identify absent monitoring as a deficiency. Satisfaction surveys measure patient experience, not clinical safety.

A patient who tolerates her patch, sleeps better, and experiences fewer hot flashes will leave a positive review. A patient who absorbs estradiol poorly and remains symptomatic may attribute the failure to "HRT not working for me" rather than to inadequate dose titration from missing serum levels. These outcomes are invisible in star ratings.

The NAMS 2022 Position Statement explicitly notes that "symptom response alone is not a reliable proxy for hormonal adequacy, and serum estradiol measurement may be warranted when clinical response is insufficient." [1] Alloy's platform as designed does not consistently apply this principle.

Clinical Bottom Line

Alloy delivers genuine value for a specific, low-complexity patient population. The formulary is guideline-concordant for first-line therapy. The price is accessible. The convenience is real.

The gaps are equally real. No baseline labs, no mandatory mammography verification, no testosterone or vaginal estrogen, no synchronous visit requirement, and no scheduled serum estradiol monitoring collectively mean that Alloy is not an appropriate single source of care for women with cardiovascular risk factors, complex symptom profiles, or any history that places them outside the standard low-risk menopausal cohort.

Women who fit the low-risk profile and want affordable, convenient access to a transdermal estradiol patch and oral progesterone will likely find Alloy sufficient. Women outside that profile should seek a platform or in-person provider who can complete the four-checkpoint assessment described above before prescribing begins.

The NAMS 2022 Position Statement sets the benchmark: hormone therapy decisions require individualization based on a woman's specific symptoms, risks, and preferences, with documented evaluation of each. [1] An intake questionnaire that takes under 10 minutes cannot fulfill that standard for every patient who clicks through it.